| Treatment under study | Study enrollment | Active completers | Placebo completers | Trial length, months |
---|---|---|---|---|---|
Mild cognitive impairment | Rofecoxib [54] | 1,457 | 687/725 = 0.95 | 702/732 = 0.96 | 48 |
 | TRIMCI study of trifusal [7] | 257 | 104/129 = 0.81 | 119/128 = 0.93 | 18 |
 | Donepezil [57] | 270 | 90/133 = 0.68 | 114/137 = 0.83 | 6 |
 | Vitamin E and donepezil [38] | 790 | 346/510 = 0.68 | 193/259 = 0.74 | 36 |
 | Rivastigmine [55] | 1,018 | 312/508 = 0.61 | 346/510 = 0.68 | 48 |
 | Donepezil [58] | 821 | 226/409 = 0.55 | 273/412 = 0.66 | 12 |
 | Two studies of galantamine [56] | 2,057 | 476/1,029 = 0.46 | 543/1,028 = 0.53 | 24 |
Mild-to-moderate AD | Dimebon [59] | 183 | 78/89 = 0.88 | 77/94 = 0.82 | 4 |
 | Gamma secretase inhibitor [62] | 51 | 32/36 = 0.89 | 12/15 = 0.80 | 4 |
 | Rosiglitazone [65] | 518 | 106/122 = 0.87 | 336/389 = 0.86 | 6 |
 | High-dose B vitamin [66] | 409 | 204/240 = 0.85 | 140/169 = 0.83 | 18 |
 | 1,195 | 704/893 = 0.79 | 266/302 = 0.88 | 6 | |
 | Estrogen replacement [6] | 120 | 65/81 = 0.80 | 32/39 = 0.82 | 15 |
 | Galantamine [69] | 978 | 539/692 = 0.78 | 240/286 = 0.84 | 5 |
 | Rofecoxib [37] | 351 | 179/240 = 0.74 | 88/111 = 0.79 | 12 |
 | DHA (Joseph Quinn, personal communication) | 402 | 178/241 = 0.74 | 129/161 = 0.80 | 18 |
 | Bapineuzumab [10] | 234 | 92/122 = 0.75 | 87/107 = 0.81 | 18 |
 | AN1792 [61] | 372 | 223/299 = 0.74 | 53/73 = 0.73 | 12 |
 | Idebenone [60] | 536 | 281/407 = 0.69 | 96/129 = 0.74 | 12 |
 | Atorvastatin [39] | 640 | 207/314 = 0.66 | 245/326 = 0.75 | 18 |
 | Galantamine [70] | 636 | 266/423 = 0.63 | 172/213 = 0.81 | 6 |
 | Tarenfl urbil [9] | 1,684 | 506/862 = 0.59 | 540/822 = 0.66 | 18 |
Moderate-to-severe/Severe AD | Selegeline/Alpha tocopherol [71] CDR 2 | 341 | 240/257 = 0.93 | 78/84 = 0.93 | 24 |
 | Donepezil [72] MMSE 5 to 17 | 291 | 121/144 = 0.84 | 126/146 = 0.86 | 6 |
 | Donepezil [5] MMSE 1 to 10 | 249 | 95/128 = 0.74 | 99/120 = 0.82 | 6 |
 | Memantine [67] MMSE 5 to 14 | 350 | 134/178 = 0.75 | 126/172 = 0.73 | 6 |
 | Memantine [12] MMSE 3 to 14 | 252 | 97/126 = 0.77 | 84/126 = 0.67 | 7 |
 | Donepezil [68] MMSE 1 to 12 | 343 | 117/176 = 0.66 | 127/167 = 0.76 | 6 |
 | Memantine [13] MMSE 5 to 14 | 404 | 172/203 = 0.85 | 150/201 = 0.75 | 6 |